TABLE 5. Reported cases of notifiable diseases and rates per 100,000, by sex, excluding U.S. territories - - United States, 2017 column labels in same order that data fields appears in each record below: Disease Female, No. Female, Rate Male, No. Male, Rate Sex not stated, No. Total, No. tab delimited data: Anthrax — — — — — — Arboviral diseases, Chikungunya virus disease 80 0.05 76 0.05 — 156 Arboviral diseases, Eastern equine encephalitis virus disease, Neuroinvasive 3 0.00 2 0.00 — 5 Arboviral diseases, Eastern equine encephalitis virus disease, Non-neuroinvasive — — — — — — Arboviral diseases, Jamestown Canyon virus disease, Neuroinvasive 25 0.02 33 0.02 — 58 Arboviral diseases, Jamestown Canyon virus disease, Non-neuroinvasive 4 0.00 13 0.01 — 17 Arboviral diseases, La Crosse virus disease, Neuroinvasive 29 0.02 34 0.02 — 63 Arboviral diseases, La Crosse virus disease, Non-neuroinvasive — — — — — — Arboviral diseases, Powassan virus disease, Neuroinvasive 5 0.00 28 0.02 — 33 Arboviral diseases, Powassan virus disease, Non-neuroinvasive 1 0.00 — — — 1 Arboviral diseases, St. Louis encephalitis virus disease, Neuroinvasive 2 0.00 4 0.00 — 6 Arboviral diseases, St. Louis encephalitis virus disease, Non-neuroinvasive 1 0.00 4 0.00 — 5 Arboviral diseases, West Nile virus disease, Neuroinvasive 515 0.31 910 0.57 — 1,425 Arboviral diseases, West Nile virus disease, Non-neuroinvasive 281 0.17 391 0.24 — 672 Arboviral diseases, Western equine encephalitis virus disease, Neuroinvasive — — — — — — Arboviral diseases, Western equine encephalitis virus disease, Non-neuroinvasive — — — — — — Babesiosis, Total 827 0.65 1,540 1.24 1 2,368 Babesiosis, Confirmed 674 0.53 1,320 1.06 — 1,994 Babesiosis, Probable 153 0.12 220 0.18 1 374 Botulism, Total 83 0.05 94 0.06 — 177 Botulism, Foodborne 8 0.00 11 0.01 — 19 Botulism, Infant * 69 3.59 68 3.37 — 137 Botulism, Other (wound & unspecified) 6 0.00 15 0.01 — 21 Brucellosis 59 0.04 81 0.05 — 140 Campylobacteriosis 31,857 19.27 35,549 22.16 131 67,537 Chancroid 3 0.00 4 0.00 — 7 Chlamydia trachomatis infection 1,127,651 682.14 577,644 360.11 3,274 1,708,569 Cholera 3 0.00 7 0.00 — 10 Coccidioidomycosis † 5,919 8.92 8,423 12.96 22 14,364 Cryptosporidiosis, Total 6,031 3.65 5,366 3.35 17 11,414 Cryptosporidiosis, Confirmed 4,220 2.55 3,808 2.37 15 8,043 Cryptosporidiosis, Probable 1,811 1.10 1,558 0.97 2 3,371 Cyclosporiasis 666 0.44 522 0.36 6 1,194 Dengue virus infections, Dengue § 212 0.13 225 0.14 — 437 Dengue virus infections, Dengue-like illness § 3 0.00 5 0.00 — 8 Dengue virus infections, Severe dengue § 4 0.00 5 0.00 — 9 Diphtheria — — — — — — Ehrlichiosis and Anaplasmosis, Anaplasma phagocytophilum infection 2,190 1.37 3,564 2.31 8 5,762 Ehrlichiosis and Anaplasmosis, Ehrlichia chaffeensis infection 651 0.41 988 0.64 3 1,642 Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection 13 0.01 32 0.02 — 45 Ehrlichiosis and Anaplasmosis, Undetermined ehrlichiosis/anaplasmosis 123 0.08 146 0.10 — 269 Giardiasis 5,792 4.46 9,354 7.43 47 15,193 Gonorrhea 232,587 140.70 322,169 200.84 852 555,608 Haemophilus influenzae, invasive disease, All ages, all serotypes 3,082 1.86 2,443 1.52 23 5,548 Haemophilus influenzae, invasive disease, Age <5 years, Serotype b ¶ 17 0.17 16 0.16 — 33 Haemophilus influenzae, invasive disease, Age <5 years, Non-b serotype ¶ 81 0.83 108 1.06 — 189 Haemophilus influenzae, invasive disease, Age <5 years, Nontypeable ¶ 89 0.91 111 1.09 — 200 Haemophilus influenzae, invasive disease, Age <5 years, Unknown serotype ¶ 91 0.93 110 1.08 2 203 Hansen's disease 27 0.02 50 0.03 17 94 Hantavirus infection, non-hantavirus pulmonary syndrome 1 0.00 1 0.00 — 2 Hantavirus pulmonary syndrome 14 0.01 19 0.01 — 33 Hemolytic uremic syndrome post-diarrheal 173 0.11 165 0.11 — 338 Hepatitis, A, acute ** 1,149 0.70 2,208 1.38 8 3,365 Hepatitis, B, acute ** 1,301 0.79 2,095 1.31 13 3,409 Hepatitis, B, perinatal infection **,†† 13 0.34 18 0.45 — 31 Hepatitis, C, acute ** 1,824 1.16 2,381 1.56 20 4,225 Hepatitis, C, acute, Confirmed ** 1,428 0.91 1,775 1.16 10 3,213 Hepatitis, C, acute, Probable ** 396 0.25 606 0.40 10 1,012 Human immunodeficiency virus diagnoses 6,428 3.89 27,510 17.15 — 33,938 Influenza-associated pediatric mortality §§ 70 0.19 56 0.15 — 126 Invasive pneumococcal disease, All ages ¶¶ 9,573 7.76 10,109 8.47 98 19,780 Invasive pneumococcal disease, All ages, Confirmed ¶¶ 9,499 7.70 10,024 8.40 97 19,620 Invasive pneumococcal disease, All ages, Probable ¶¶ 74 0.06 85 0.07 1 160 Invasive pneumococcal disease, Age <5 years ¶¶,¶ 528 0.40 700 0.55 6 1,234 Invasive pneumococcal disease, Age <5 years, Confirmed ¶¶,¶ 522 6.69 692 8.48 6 1,220 Invasive pneumococcal disease, Age <5 years, Probable ¶¶,¶ 6 0.08 8 0.10 — 14 Legionellosis 2,865 1.73 4,589 2.86 4 7,458 Leptospirosis 18 0.01 54 0.04 — 72 Listeriosis 482 0.29 401 0.25 4 887 Lyme disease, Total 17,710 10.76 24,392 15.27 641 42,743 Lyme disease, Confirmed 12,152 7.38 16,920 10.60 441 29,513 Lyme disease, Probable 5,558 3.38 7,472 4.68 200 13,230 Malaria 756 0.46 1,296 0.81 4 2,056 Measles, Total 52 0.03 66 0.04 2 120 Measles, Indigenous 40 0.02 57 0.04 2 99 Measles, Imported 12 0.01 9 0.01 — 21 Meningococcal disease, All serogroups 168 0.10 184 0.11 1 353 Meningococcal disease, Serogroups ACWY 54 0.03 53 0.03 — 107 Meningococcal disease, Serogroup B 44 0.03 46 0.03 — 90 Meningococcal disease, Other serogroups 11 0.01 14 0.01 — 25 Meningococcal disease, Unknown serogroup 59 0.04 71 0.04 1 131 Mumps 2,766 1.67 3,336 2.08 7 6,109 Novel Influenza A virus infections 34 0.02 32 0.02 — 66 Pertussis 10,348 6.26 8,589 5.35 38 18,975 Plague 2 0.00 3 0.00 — 5 Poliomyelitis, paralytic — — — — — — Poliovirus infection, nonparalytic — — — — — — Psittacosis 4 0.00 1 0.00 — 5 Q fever, Total 51 0.03 142 0.09 — 193 Q fever, Acute 35 0.02 118 0.07 — 153 Q fever, Chronic 16 0.01 24 0.02 — 40 Rabies, Human 2 0.00 — — — 2 Rubella 4 0.00 3 0.00 — 7 Rubella, congenital syndrome * 2 0.10 3 0.15 — 5 Salmonellosis 28,850 17.45 25,195 15.71 240 54,285 Severe acute respiratory syndrome-associated coronavirus disease — — — — — — Shiga toxin-producing Escherichia coli *** 4,527 2.74 4,127 2.57 18 8,672 Shigellosis 6,628 4.01 8,232 5.13 52 14,912 Smallpox — — — — — — Spotted fever rickettsiosis, Total 2,289 1.39 3,956 2.48 3 6,248 Spotted fever rickettsiosis, Confirmed 64 0.04 112 0.07 — 176 Spotted fever rickettsiosis, Probable 2,225 1.35 3,844 2.41 3 6,072 Streptococcal toxic shock syndrome 167 0.16 205 0.20 — 372 Syphilis, Total, all stages 18,146 10.98 82,314 51.32 1,107 101,567 Syphilis, Congenital * — — — — 918 918 Syphilis, Primary and secondary 3,722 2.25 26,885 16.76 37 30,644 Tetanus 17 0.01 16 0.01 — 33 Toxic shock syndrome (other than Streptococcal) 20 0.02 9 0.01 1 30 Trichinellosis 5 0.00 10 0.01 — 15 Tuberculosis 3,515 2.13 5,584 3.48 6 9,105 Tularemia 94 0.06 145 0.09 — 239 Typhoid fever 191 0.12 227 0.14 1 419 Vancomycin-intermediate Staphylococcus aureus 43 0.03 65 0.05 1 109 Vancomycin-resistant Staphylococcus aureus — — 3 0.00 — 3 Varicella morbidity 4,281 3.17 4,446 3.39 48 8,775 Varicella mortality U U U U U U Vibriosis, Total 812 0.50 1,266 0.80 7 2,085 Vibriosis, Confirmed 525 0.32 965 0.61 7 1,497 Vibriosis, Probable 287 0.18 301 0.19 — 588 Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus — — — — — — Viral hemorrhagic fevers, Ebola virus — — — — — — Viral hemorrhagic fevers, Guanarito virus — — — — — — Viral hemorrhagic fevers, Junin virus — — — — — — Viral hemorrhagic fevers, Lassa virus — — — — — — Viral hemorrhagic fevers, Lujo virus — — — — — — Viral hemorrhagic fevers, Machupo virus — — — — — — Viral hemorrhagic fevers, Marburg virus — — — — — — Viral hemorrhagic fevers, Sabia virus — — — — — — Yellow fever — — — — — — Zika virus, Zika virus disease, congenital *,††† 7 0.36 15 0.74 — 22 Zika virus, Zika virus disease, non-congenital 324 0.20 173 0.11 — 497 Zika virus, Zika virus infection, congenital *,††† 8 0.42 9 0.45 — 17 Zika virus, Zika virus infection, non-congenital 599 0.36 42 0.03 — 641 —: No reported cases - The reporting jurisdiction did not submit any cases to CDC. U: Unavailable - The data are unavailable. * The rate is calculated using population less than 1 year of age. † Reportable in <25 states. § Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM). ¶ The rate is calculated using population less than 5 years of age. ** Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm. †† The rate is calculated using population less than 2 years of age. §§ The rate is calculated using population less than 18 years of age. ¶¶ Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years. *** Includes Escherichia coli O157:H7 and Shiga toxin-positive Escherichia coli (including O157, non-O157, and not serogrouped). ††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/pregnancy/zika/data/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection. Notes: These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. The list of nationally notifiable infectious diseases and conditions for 2018 and their national surveillance case definitions are available by navigating to the https://ndc.services.cdc.gov/, Surveillance Case Definitions | CDC web page, selecting "2017" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2016 by CSTE for national surveillance, that were implemented in January 2017, including updated surveillance case definitions for salmonellosis, shigellosis, vibrioisis, perinatal hepatitis B virus infection, invasive pneumococcal disease, Lyme disease, and tularemia reported through August 7, 2018. Publication criteria for the finalized 2017 data are available at https://wonder.cdc.gov/nndss/documents/2017_NNDSS_Publication_Criteria.pdf, https://wonder.cdc.gov/nndss/documents/2017_NNDSS_Publication_Criteria.pdf. See also https://ndc.services.cdc.gov/wp-content/uploads/Users_guide_WONDER_tables_cleared_final.pdf, Guide to Interpreting Provisional and Finalized NNDSS Data. Population estimates for incidence rates are July 1st, 2017 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010 - July 1, 2017, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2017), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released June 27, 2018 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm, https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2017 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on October 2, 2018 at https://www.census.gov/data-tools/demo/idb/informationGateway.php, https://www.census.gov/data-tools/demo/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation. Annual tables for 2016 and later years are available on https://wonder.cdc.gov/nndss/nndss_annual_tables_menu.asp, CDC WONDER. Annual summary reports from 1993-2015 are available as published in the https://www.cdc.gov/mmwr/mmwr_nd/index.html, MMWR. NNDSS annual tables since 1952 are available at https://stacks.cdc.gov/nndss, CDC Stacks (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left). Suggested Citation: Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2017 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Division of Health Informatics and Surveillance, 2018. Available at: https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html, https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html. https://www.cdc.gov/nndss/, National Notifiable Diseases Surveillance System Provided by https://wonder.cdc.gov, CDC WONDER